Literature DB >> 19577010

A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis.

Dan Turner1, Cynthia H Seow, Gordon R Greenberg, Anne M Griffiths, Mark S Silverberg, A Hillary Steinhart.   

Abstract

BACKGROUND & AIMS: There is no reliable standard of disease activity in ulcerative colitis (UC). We performed a prospective study to systematically compare all non-invasive disease activity indices in patients with UC and to identify cutoff scores that correspond to remission and response.
METHODS: The study included adults with UC (n = 86; 52% males, mean age 37.6 +/- 13.7 years). Items from the following indices were scored: partial Mayo score, Rachmilewitz, Lichtiger, Seo, Pediatric Ulcerative Colitis Activity Index (PUCAI), Partial Powell-Tuck, Endoscopic-Clinical Correlation, Beattie, and Walmsley. Physician and patient global assessments, colonoscopic scores, blood test data, and the full Mayo scores were used to assess construct and discriminative validity. A follow-up evaluation of 61 patients was used to assess test-retest reliability and responsiveness.
RESULTS: The Walmsley index and PUCAI were best in assessing disease activity, determined by all 4 clinimetric properties. In assessing validity, the mean correlation coefficients for the 5 included constructs were r = 0.80 and r = 0.79 for the Walmsley and PUCAI, respectively (P < .001 for each). The partial Mayo score accurately determined disease activity in 3 of the 4 clinimetric properties; the Rachmilewitz index accurately assessed patients in 2 of the properties. Cutoff scores that defined combined clinical-endoscopic remission and response were determined using receiver operating characteristic curve analyses for all instruments.
CONCLUSIONS: The Walmsley index and PUCAI are valid, reliable and responsive noninvasive measures to assess disease activity in adults with UC. Given their robust clinimetric properties, use of these indices might permit less-frequent endoscopic assessment in patients with UC-both in research and in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19577010     DOI: 10.1016/j.cgh.2009.06.024

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  39 in total

1.  Exercise decreases risk of future active disease in patients with inflammatory bowel disease in remission.

Authors:  Patricia D Jones; Michael D Kappelman; Christopher F Martin; Wenli Chen; Robert S Sandler; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325

2.  Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity.

Authors:  Cynthia E Cherfane; Luke Gessel; Dominic Cirillo; Miriam B Zimmerman; Steven Polyak
Journal:  Inflamm Bowel Dis       Date:  2015-08       Impact factor: 5.325

3.  Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study.

Authors:  Ignacio Marín-Jiménez; Pilar Nos; Eugeni Domènech; Sabino Riestra; Javier P Gisbert; Xavier Calvet; Xavier Cortés; Eva Iglesias; Jose M Huguet; Carlos Taxonera; Ramón Fernández; Daniel Carpio; Ana Gutiérrez; Jordi Guardiola; Luisa Castro Laria; Beatriz Sicilia; Luis Bujanda; Luis Cea-Calvo; Cristina Romero; Óscar Rincón; Berta Juliá; Julián Panés
Journal:  Am J Gastroenterol       Date:  2016-01-12       Impact factor: 10.864

4.  Impact of pain on health-related quality of life in patients with inflammatory bowel disease.

Authors:  Anja Schirbel; Anne Reichert; Stephanie Roll; Daniel C Baumgart; Carsten Büning; Bianca Wittig; Bertram Wiedenmann; Axel Dignass; Andreas Sturm
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

5.  An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index.

Authors:  Meenakshi Bewtra; Colleen M Brensinger; Vesselin T Tomov; Tram B Hoang; Carly E Sokach; Corey A Siegel; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2014-06       Impact factor: 5.325

6.  Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis.

Authors:  Dong Suk Shin; Jae Hee Cheon; Yong Eun Park; Yehyun Park; Soo Jung Park; Tae Il Kim; Won Ho Kim
Journal:  Dig Dis Sci       Date:  2018-08-25       Impact factor: 3.199

7.  Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis.

Authors:  Boyko Kabakchiev; Dan Turner; Jeffrey Hyams; David Mack; Neal Leleiko; Wallace Crandall; James Markowitz; Anthony R Otley; Wei Xu; Pingzhao Hu; Anne M Griffiths; Mark S Silverberg
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

8.  Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Panagiotis Georgoulias; Chara Tzavara; Varvara Valotassiou; Anastasia Kapsoritaki; Spyros P Potamianos
Journal:  BMC Gastroenterol       Date:  2010-10-14       Impact factor: 3.067

9.  Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission.

Authors:  Laura Rosenberg; Garrett O Lawlor; Talia Zenlea; Jeffrey D Goldsmith; Anne Gifford; Kenneth R Falchuk; Jacqueline L Wolf; Adam S Cheifetz; Simon C Robson; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

10.  Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease.

Authors:  Matthew Geisz; Christina Ha; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Robert S Sandler; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.